TABLE OF CONTENTS I
LIST OF FIGURES XVIII
LIST OF CHARTS XXIV
EXECUTIVE SUMMARY 1
EUROPEAN MARKET FOR VASCULAR ACCESS DEVICES AND ACCESSORIES OVERVIEW 1
COMPETITIVE ANALYSIS 3
MARKET TRENDS 5
MARKET DEVELOPMENTS 6
PROCEDURE NUMBERS 7
MARKETS INCLUDED 8
KEY REPORT UPDATES 11
VERSION HISTORY 12
RESEARCH METHODOLOGY 13
1.1 RESEARCH SCOPE 13
1.2 IDATA’S 9-STEP METHODOLOGY 13
Step 1: Project Initiation & Team Selection 13
Step 2: Prepare Data Systems and Perform Secondary Research 15
Step 3: Preparation for Interviews & Questionnaire Design 16
Step 4: Performing Primary Research 17
Step 5: Research Analysis: Establishing Baseline Estimates 19
Step 6: Market Forecast and Analysis 20
Step 7: Identify Strategic Opportunities 22
Step 8: Final Review and Market Release 23
Step 9: Customer Feedback and Market Monitoring 24
DISEASE OVERVIEW 25
2.1 BASIC ANATOMY 25
2.1.1 Human Vascular System 25
2.2 VASCULAR PATHOLOGY AND DISORDERS 26
2.2.1 Cancer 26
2.2.2 End-Stage Renal Disease 27
2.2.3 Diabetes 29
PRODUCT ASSESSMENT 32
3.1 PRODUCT PORTFOLIOS 32
3.1.1 Syringe and Needles 32
3.1.1.1 Introduction 32
3.1.1.2 Allison Medical 34
3.1.1.2.1 SureComfort™ 34
3.1.1.3 B. Braun 34
3.1.1.3.1 Injekt® 34
3.1.1.3.2 Other Syringe & Needle Offerings 34
3.1.1.4 Becton Dickinson 34
3.1.1.4.1 BD™ Insulin Syringes 34
3.1.1.4.2 BD™ Allergy Syringes 35
3.1.1.4.3 BD™ Tuberculin Syringes 35
3.1.1.4.4 BD™ Syringes & Needles 35
3.1.1.4.5 BD PrecisionGlide™ Needles 35
3.1.1.4.6 BD Safety-Lok™ Syringes 35
3.1.1.4.7 BD SafetyGlide™ Syringes & Needles 36
3.1.1.4.8 BD Eclipse™ Needles and Syringes 36
3.1.1.4.9 BD Integra™ Needles and Syringes 36
3.1.1.4.10 BD AutoShield™ 36
3.1.1.4.11 Ultra-Fine™ 36
3.1.1.5 Cardinal Health 36
3.1.1.5.1 Cardinal Health™ 36
3.1.1.6 Delta Hi-Tech, Inc. 37
3.1.1.6.1 AIMSCO® 37
3.1.1.7 Medical Plastic Devices, Inc. 37
3.1.1.7.1 Insupen® 37
3.1.1.8 Medtronic 37
3.1.1.8.1 Magellan™ 37
3.1.1.8.2 Monoject™ 37
3.1.1.9 MYCO Medical 38
3.1.1.9.1 Dispovan® 38
3.1.1.10 Nipro Medical 38
3.1.1.10.1 Nipro™ 38
3.1.1.11 Novo Nordisk 38
3.1.1.11.1 NovoFine® 38
3.1.1.11.2 NovoTwist® 38
3.1.1.12 Owen Mumford, Inc. 38
3.1.1.12.1 Unifine® 38
3.1.1.13 Perrigo 39
3.1.1.13.1 Clickfine® 39
3.1.1.14 Protectus Medical Devices 39
3.1.1.14.1 Protectus® 39
3.1.1.15 ReliOn 39
3.1.1.15.1 ReliOn® 39
3.1.1.16 Retractable Technologies, Inc. 39
3.1.1.16.1 VanishPoint® 39
3.1.1.16.2 Patient Safe® 39
3.1.1.17 Revolutions Medical 40
3.1.1.17.1 ReVac™ 40
3.1.1.18 Safety 1st Medical 40
3.1.1.18.1 Safe-1® 40
3.1.1.19 Smiths Medical 40
3.1.1.19.1 Needle-Pro® 40
3.1.1.20 SOL-MILLENNIUM 40
3.1.1.20.1 SOL-CARE® 40
3.1.1.20.2 SOL-M™ 41
3.1.1.20.3 SOL-GUARD™ 41
3.1.1.21 STAT Medical Devices 41
3.1.1.21.1 Super-Fine™ 41
3.1.1.22 Terumo 42
3.1.1.22.1 SurGuard® 42
3.1.1.22.2 TERUMO® 42
3.1.1.23 UltiCare 42
3.1.1.23.1 UltiCare® 42
3.2 REGULATORY ISSUES AND RECALLS 43
3.2.1 November 2015 43
3.2.2 October 2015 43
3.2.3 September 2015 44
3.2.4 August 2015 46
3.2.5 July 2015 47
3.2.6 April 2015 49
3.2.7 March 2015 50
3.2.8 February 2015 51
3.2.9 January 2015 51
3.2.10 December 2014 52
3.2.11 October 2014 53
3.2.12 September 2014 54
3.2.13 May 2014 55
3.2.14 April 2014 55
3.2.15 March 2014 56
3.2.16 January 2014 56
3.2.17 December 2013 57
3.2.18 September 2013 58
3.2.19 August 2013 59
3.2.20 June 2013 59
3.2.21 March 2013 60
3.2.22 February 2013 61
3.2.23 December 2012 61
3.2.24 August 2012 61
3.2.25 June 2012 62
3.2.26 May 2012 63
3.2.27 March 2012 64
3.2.28 February 2012 65
3.2.29 January 2012 65
3.3 CLINICAL TRIALS 69
3.3.1 Syringe and Needles 70
3.4 PRODUCT PIPELINES 80
3.4.1 Alliance Vascular Devices, LLC 80
3.4.1.1 FreeHand Safety Huber Needle® 80
3.4.2 AngioDynamics 80
3.4.2.1 Celerity™ PICC Tip Confirmation System with Navigation 80
3.4.2.2 Firefly 80
3.4.2.3 BioFlo® PICC Line Extension 81
3.4.2.4 BioFlo® Port Line Extension 81
3.4.2.5 Next Generation BioFlo® PICC 81
3.4.2.6 Next Generation BioFlo® Port 81
3.4.3 Bluegrass Vascular Technologies, Inc. 81
3.4.3.1 Surfacer® Inside-Out™ Access System 81
3.4.4 C.R. Bard 81
3.4.4.1 Chemical-Resistant PICCs 81
3.4.4.2 Novel Advanced Material PICCs 82
3.4.4.3 PowerGlide® Pro Midline 82
3.4.4.4 AccuCath® 82
3.4.4.5 Xenesis™ Acute Hemodialysis Catheter 82
3.4.4.6 Site~Rite® 8 Ultrasound System 82
3.4.5 M. C. Johnson 82
3.4.5.1 PICC Securement Device 82
3.4.6 Nipro Medical 83
3.4.6.1 Shielding Safety Needle 83
3.4.6.2 Safety Syringe 83
3.4.6.3 Safety PIVC 83
3.4.7 Parasol Medical 83
3.4.7.1 Catheter Securement Device 83
3.4.8 PAVmed Inc. 83
3.4.8.1 NextCath™ 83
3.4.9 Phase One Medical 83
3.4.9.1 Goldilocks™ Long Term Hemodialysis Catheter 83
3.4.9.2 Triple-Lumen Symetrex™ Hemodialysis Catheter 84
3.4.10 Prodigy Diabetes Care, LLC. 84
3.4.10.1 Insulin Pen Needles 84
3.4.11 Sharklet Technologies, Inc. 84
3.4.11.1 Sharklet™ Central Venous Catheter 84
3.4.12 Starboard Medical 84
3.4.12.1 Catheter Securement Devices 84
3.4.13 Teleflex Medical 85
3.4.13.1 Arrow® Endurance™ Extended Dwell Peripheral Catheter System 85
3.4.13.2 Tip Confirmation for CVCs, Chronic Hemodialysis Catheters & Ports 85
3.4.14 Vascular Access Technologies, Inc. 85
3.4.14.1 SAFECVAD™ 85
COUNTRY PROFILES 86
4.1 INTRODUCTION 86
4.1.1 Population 86
4.1.2 GDP Per Capita 86
4.1.3 Price Index 86
4.2 GERMANY 87
4.3 FRANCE 88
4.4 UNITED KINGDOM 89
4.5 ITALY 90
4.6 SPAIN 91
4.7 BENELUX 92
4.8 SCANDINAVIA 93
4.9 AUSTRIA 94
4.10 SWITZERLAND 95
4.11 PORTUGAL 96
SYRINGE AND NEEDLE MARKET 97
5.1 INTRODUCTION 97
5.1.1 Two-Part and Three-Part Syringes 98
5.1.2 Safety Devices 98
5.1.3 Insulin Syringes 99
5.2 MARKET OVERVIEW 100
5.3 MARKET ANALYSIS AND FORECAST 104
5.3.1 Total Syringe and Needle Market 104
5.3.2 Total Syringe Market 112
5.3.2.1 Total Conventional Syringe Market 119
5.3.2.1.1 Two-Part Conventional Syringe Market 127
5.3.2.1.2 Three-Part Conventional Syringe Market 134
5.3.2.2 Safety Syringe Market 141
5.3.2.3 Total Insulin Syringe Market 149
5.3.2.3.1 Insulin Syringe with Needle Market 157
5.3.2.3.2 Insulin Syringe without Needle Market 158
5.3.3 Total Needle Market 159
5.3.3.1 Conventional Needle Market 166
5.3.3.2 Safety Needle Market 174
5.3.3.3 Blunt Type Needle Market 182
5.4 DRIVERS AND LIMITERS 184
5.4.1 Market Drivers 184
5.4.2 Market Limiters 185
5.5 COMPETITIVE MARKET SHARE ANALYSIS 188
ABBREVIATIONS 194
APPENDIX: COMPANY PRESS RELEASES 196

Chart 1 1: Vascular Access Device and Accessories Market by Segment, Europe, 2013 – 2023 2
Chart 1 2: Vascular Access Device and Accessories Market Overview, Europe, 2016 & 2023 2
Chart 4 1: Country Profile, Germany, 2016 87
Chart 4 2: Country Profile, France, 2016 88
Chart 4 3: Country Profile, United Kingdom, 2016 89
Chart 4 4: Country Profile, Italy, 2016 90
Chart 4 5: Country Profile, Spain, 2016 91
Chart 4 6: Country Profile, Benelux, 2016 92
Chart 4 7: Country Profile, Scandinavia, 2016 93
Chart 4 8: Country Profile, Austria, 2016 94
Chart 4 9: Country Profile, Switzerland, 2016 95
Chart 4 10: Country Profile, Portugal, 2016 96
Chart 5 1: Syringe and Needle Market by Segment, Europe, 2013 – 2023 102
Chart 5 2: Syringe and Needle Market by Segment, Europe, 2016 103
Chart 5 3: Syringe and Needle Market by Segment, Europe, 2023 103
Chart 5 4: Total Syringe and Needle Market, Europe, 2013 – 2023 106
Chart 5 5: Total Conventional Syringe Market, Europe, 2013 – 2023 121
Chart 5 6: Safety Syringe Market, Europe, 2013 – 2023 143
Chart 5 7: Total Insulin Syringe Market, Europe, 2013 – 2023 151
Chart 5 8: Conventional Needle Market, Europe, 2013 – 2023 168
Chart 5 9: Safety Needle Market, Europe, 2013 – 2023 176
Chart 5 10: Blunt Type Needle Market, Europe, 2013 – 2023 183
Chart 5 11: Leading Competitors, Syringe and Needle Market, Europe, 2016 193

Figure 1 1: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, Europe, 2016 (1 of 2) 3
Figure 1 2: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, Europe, 2016 (2 of 2) 3
Figure 1 3: Companies Researched in this Report, Europe, 2016 4
Figure 1 4: Factors Impacting the Vascular Access Device and Accessories Market by Segment, Europe, 2016 5
Figure 1 5: Recent Events in the Vascular Access Device and Accessories Market, Europe, 2013 – 2016 6
Figure 1 6: Vascular Access Procedures Covered, Europe, 2016 7
Figure 1 7: Vascular Access Device and Accessories Markets Covered, Europe, 2016 (1 of 3) 8
Figure 1 8: Vascular Access Device and Accessories Markets Covered, Europe, 2016 (2 of 3) 9
Figure 1 9: Vascular Access Device and Accessories Markets Covered, Europe, 2016 (3 of 3) 10
Figure 1 10: Key Report Updates 11
Figure 1 11: Version History 12
Figure 3 1: Class 2 Device Recall Medtronic 43
Figure 3 2: Class 2 Device Recall Smiths Medical 43
Figure 3 3: Class 2 Device Recall Arrow 44
Figure 3 4: Class 2 Device Recall Arrow 44
Figure 3 5: Class 2 Device Recall Covidien (Medtronic) 45
Figure 3 6: Class 2 Device Recall Arrow 46
Figure 3 7: Class 2 Device Recall Medline 46
Figure 3 8: Class 2 Device Recall Arrow 46
Figure 3 9: Class 2 Device Recall B. Braun 46
Figure 3 10: Class 3 Device Recall Bard Access 47
Figure 3 11: Class 2 Device Recall Covidien (Medtronic) 47
Figure 3 12: Class 2 Device Recall Bard Access 49
Figure 3 13: Class 2 Device Recall Bard Access 49
Figure 3 14: Class 2 Device Recall Medcomp & AngioDynamics 50
Figure 3 15: Class 2 Device Recall Bard Access 50
Figure 3 16: Class 2 Device Recall Arrow 51
Figure 3 17: Class 2 Device Recall Medcomp 51
Figure 3 18: Class 2 Device Recall Arrow 51
Figure 3 19: Class 2 Device Recall Arrow 52
Figure 3 20: Class 2 Device Recall Smiths Medical 52
Figure 3 21: Class 2 Device Recall PFM Medical 52
Figure 3 22: Class 2 Device Recall PFM Medical 52
Figure 3 23: Class 2 Device Recall Becton Dickinson 53
Figure 3 24: Class 2 Device Recall Arrow 53
Figure 3 25: Class 2 Device Recall Arrow 53
Figure 3 26: Class 2 Device Recall Navilyst Medical 53
Figure 3 27: Class 2 Device Recall Argon Medical 54
Figure 3 28: Class 2 Device Recall Arrow 55
Figure 3 29: Class 2 Device Recall Arrow 55
Figure 3 30: Class 2 Device Recall Arrow 56
Figure 3 31: Class 2 Device Recall Bard Access 56
Figure 3 32: Class 2 Device Recall Navilyst Medical 56
Figure 3 33: Class 2 Device Recall Bard Access 57
Figure 3 34: Class 2 Device Recall Smiths Medical 57
Figure 3 35: Class 2 Device Recall B. Braun 57
Figure 3 36: Class 2 Device Recall Smiths Medical 58
Figure 3 37: Class 2 Device Recall Access Scientific 58
Figure 3 38: Class 2 Device Recall Covidien (Medtronic) 58
Figure 3 39: Class 2 Device Recall Arrow 59
Figure 3 40: Class 2 Device Recall Bard Access 59
Figure 3 41: Class 2 Device Recall Becton Dickinson 59
Figure 3 42: Class 2 Device Recall Churchill Medical Systems, Inc. A Vygon Company 60
Figure 3 43: Class 2 Device Recall Bard Access 60
Figure 3 44: Class 2 Device Recall Churchill Medical Systems, Inc. A Vygon Company 60
Figure 3 45: Class 2 Device Recall Medcomp 61
Figure 3 46: Class 2 Device Recall Becton Dickinson 61
Figure 3 47: Class 3 Device Recall Bard Access 61
Figure 3 48: Class 2 Device Recall Medcomp 62
Figure 3 49: Class 1 Device Recall Arrow 62
Figure 3 50: Class 2 Device Recall Arrow 62
Figure 3 51: Class 2 Device Recall Vygon 62
Figure 3 52: Class 2 Device Recall Covidien (Medtronic) 63
Figure 3 53: Class 2 Device Recall Medcomp 64
Figure 3 54: Class 2 Device Recall Churchill Medical Systems, Inc. A Vygon Company 64
Figure 3 55: Class 2 Device Recall Christie Medical Holdings 64
Figure 3 56: Class 3 Recall Bard Access 64
Figure 3 57: Class 2 Device Recall AngioDynamics 65
Figure 3 58: Class 2 Device Recall Becton Dickinson 65
Figure 3 59: Class 2 Device Recall AngioDynamics 65
Figure 3 60: Class 2 Device Recall AngioDynamics 67
Figure 3 61: Class 3 Device Recall AngioDynamics 68
Figure 3 62: Class 2 Device Recall AngioDynamics 68
Figure 3 63: A Randomized, Parallel Design Study 70
Figure 3 64: Pen Torch Transillumination: Shedding Light on Difficult Venepuncture 70
Figure 3 65: Transition From Parenteral Prostanoids to Inhaled Treprostinil 71
Figure 3 66: Efficacy, Safety and Acceptability of the New Pen Needle 71
Figure 3 67: A Phase I Study of the Safety, Reactogenicity, Acceptability and Immunogenicity 72
Figure 3 68: A Single Centre, Randomised, 3-period Cross-over Trial 72
Figure 3 69: A Phase IV, Non-Inferiority, Observer Blind, Randomized Clinical Study 73
Figure 3 70: Treating Diabetic Lipohypertrophy With Intensive Education 73
Figure 3 71: Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin 74
Figure 3 72: A Randomized, Multi-centre Cross-over Study 74
Figure 3 73: A Clinical Investigation to Evaluate the Safety and Performance 75
Figure 3 74: A Phase I, Randomized, Open-Label, Parallel-Group, Single-Dose, Multi-Center Study 75
Figure 3 75: Pharmacokinetic and Pharmacodynamic Profile of Insulin Lispro 76
Figure 3 76: Reproducibility of Insulin Action When Administered by Needle-free Jet Injection 76
Figure 3 77: Patient Experiences With Injection Needles 77
Figure 3 78: Inactivated Influenza Via Jet Injection 77
Figure 3 79: Intradermal Rabies Immunization Using NanoJect: A Comparative Study 78
Figure 3 80: Phase 1b, Partial-Blind, Parallel Group, Randomized Study 78
Figure 3 81: A Phase I, Open Label, CT to Evaluate the Safety, Tolerability and Immunogenicity 79
Figure 5 1: Syringe and Needle Market by Segment, Europe, 2013 – 2023 (€M) 101
Figure 5 2: Syringe and Needle Market by Segment, Europe, 2013 – 2023 (US$M) 101
Figure 5 3: Total Syringe and Needle Market, Europe, 2013 – 2023 (€ and US$) 105
Figure 5 4: Units Sold by Country, Total Syringe and Needle Market, Europe, 2013 – 2023 107
Figure 5 5: Average Selling Price by Country, Total Syringe and Needle Market, Europe, 2013 – 2023 (€) 108
Figure 5 6: Average Selling Price by Country, Total Syringe and Needle Market, Europe, 2013 – 2023 (US$) 109
Figure 5 7: Market Value by Country, Total Syringe and Needle Market, Europe, 2013 – 2023 (€M) 110
Figure 5 8: Market Value by Country, Total Syringe and Needle Market, Europe, 2013 – 2023 (US$M) 111
Figure 5 9: Total Syringe Market, Europe, 2013 – 2023, (€ and US$) 113
Figure 5 10: Units Sold by Country, Total Syringe Market, Europe, 2013 – 2023 114
Figure 5 11: Average Selling Price by Country, Total Syringe Market, Europe, 2013 – 2023 (€) 115
Figure 5 12: Average Selling Price by Country, Total Syringe Market, Europe, 2013 – 2023 (US$) 116
Figure 5 13: Market Value by Country, Total Syringe Market, Europe, 2013 – 2023 (€M) 117
Figure 5 14: Market Value by Country, Total Syringe Market, Europe, 2013 – 2023 (US$M) 118
Figure 5 15: Total Conventional Syringe Market, Europe, 2013 – 2023, (€ and US$) 120
Figure 5 16: Units Sold by Country, Total Conventional Syringe Market, Europe, 2013 – 2023 122
Figure 5 17: Average Selling Price by Country, Total Conventional Syringe Market, Europe, 2013 – 2023 (€) 123
Figure 5 18: Average Selling Price by Country, Total Conventional Syringe Market, Europe, 2013 – 2023 (US$) 124
Figure 5 19: Market Value by Country, Total Conventional Syringe Market, Europe, 2013 – 2023 (€M) 125
Figure 5 20: Market Value by Country, Total Conventional Syringe Market, Europe, 2013 – 2023 (US$M) 126
Figure 5 21: Two-Part Conventional Syringe Market, Europe, 2013 – 2023 (€ and US$) 128
Figure 5 22: Units Sold by Country, Two-Part Conventional Syringe Market, Europe, 2013 – 2023 129
Figure 5 23: Average Selling Price by Country, Two-Part Conventional Syringe Market, Europe, 2013 – 2023 (€) 130
Figure 5 24: Average Selling Price by Country, Two-Part Conventional Syringe Market, Europe, 2013 – 2023 (US$) 131
Figure 5 25: Market Value by Country, Two-Part Conventional Syringe Market, Europe, 2013 – 2023 (€M) 132
Figure 5 26: Market Value by Country, Two-Part Conventional Syringe Market, Europe, 2013 – 2023 (US$M) 133
Figure 5 27: Three-Part Conventional Syringe Market, Europe, 2013 – 2023 (€ and US$) 135
Figure 5 28: Units Sold by Country, Three-Part Conventional Syringe Market, Europe, 2013 – 2023 136
Figure 5 29: Average Selling Price by Country, Three-Part Conventional Syringe Market, Europe, 2013 – 2023 (€) 137
Figure 5 30: Average Selling Price by Country, Three-Part Conventional Syringe Market, Europe, 2013 – 2023 (US$) 138
Figure 5 31: Market Value by Country, Three-Part Conventional Syringe Market, Europe, 2013 – 2023 (€M) 139
Figure 5 32: Market Value by Country, Three-Part Conventional Syringe Market, Europe, 2013 – 2023 (US$M) 140
Figure 5 33: Safety Syringe Market, Europe, 2013 – 2023 (€ and US$) 142
Figure 5 34: Units Sold by Country, Safety Syringe Market, Europe, 2013 – 2023 144
Figure 5 35: Average Selling Price by Country, Safety Syringe Market, Europe, 2013 – 2023 (€) 145
Figure 5 36: Average Selling Price by Country, Safety Syringe Market, Europe, 2013 – 2023 (US$) 146
Figure 5 37: Market Value by Country, Safety Syringe Market, Europe, 2013 – 2023 (€M) 147
Figure 5 38: Market Value by Country, Safety Syringe Market, Europe, 2013 – 2023 (US$M) 148
Figure 5 39: Total Insulin Syringe Market, Europe, 2013 – 2023 (€ and US$) 150
Figure 5 40: Units Sold by Country, Total Insulin Syringe Market, Europe, 2013 – 2023 152
Figure 5 41: Average Selling Price by Country, Total Insulin Syringe Market, Europe, 2013 – 2023 (€) 153
Figure 5 42: Average Selling Price by Country, Total Insulin Syringe Market, Europe, 2013 – 2023 (US$) 154
Figure 5 43: Market Value by Country, Total Insulin Syringe Market, Europe, 2013 – 2023 (€M) 155
Figure 5 44: Market Value by Country, Total Insulin Syringe Market, Europe, 2013 – 2023 (US$M) 156
Figure 5 45: Insulin Syringe with Needle Market, Europe, 2013 – 2023 (€ and US$) 157
Figure 5 46: Insulin Syringe without Needle Market, Europe, 2013 – 2023 (€ and US$) 158
Figure 5 47: Total Needle Market, Europe, 2013 – 2023 (€ and US$) 160
Figure 5 48: Units Sold by Country, Total Needle Market, Europe, 2013 – 2023 161
Figure 5 49: Average Selling Price by Country, Total Needle Market, Europe, 2013 – 2023 (€) 162
Figure 5 50: Average Selling Price by Country, Total Needle Market, Europe, 2013 – 2023 (US$) 163
Figure 5 51: Market Value by Country, Total Needle Market, Europe, 2013 – 2023 (€M) 164
Figure 5 52: Market Value by Country, Total Needle Market, Europe, 2013 – 2023 (US$M) 165
Figure 5 53: Conventional Needle Market, Europe, 2013 – 2023 (€ and US$) 167
Figure 5 54: Units Sold by Country, Conventional Needle Market, Europe, 2013 – 2023 169
Figure 5 55: Average Selling Price by Country, Conventional Needle Market, Europe, 2013 – 2023 (€) 170
Figure 5 56: Average Selling Price by Country, Conventional Needle Market, Europe, 2013 – 2023 (US$) 171
Figure 5 57: Market Value by Country, Conventional Needle Market, Europe, 2013 – 2023 (€M) 172
Figure 5 58: Market Value by Country, Conventional Needle Market, Europe, 2013 – 2023 (US$M) 173
Figure 5 59: Safety Needle Market, Europe, 2013 – 2023 (€ and US$) 175
Figure 5 60: Units Sold by Country, Safety Needle Market, Europe, 2013 – 2023 177
Figure 5 61: Average Selling Price by Country, Safety Needle Market, Europe, 2013 – 2023 (€) 178
Figure 5 62: Average Selling Price by Country, Safety Needle Market, Europe, 2013 – 2023 (US$) 179
Figure 5 63: Market Value by Country, Safety Needle Market, Europe, 2013 – 2023 (€M) 180
Figure 5 64: Market Value by Country, Safety Needle Market, Europe, 2013 – 2023 (US$M) 181
Figure 5 65: Blunt Type Needle Market, Europe, 2013 – 2023 (€ and US$) 182
Figure 5 66: Drivers and Limiters, Syringe and Needle Market, Europe, 2016 186
Figure 5 67: Leading Competitors by Country, Syringe and Needle Market, Europe, 2016 192
Figure 7 1: Press Release Summary 196

3DT Holdings LLC
3M
Access Scientific
Ambu Inc.
AngioDynamics
Artsana
B. Braun
Baxter International
Becton Dickinson
Bionic
C. R. Bard
Cardinal Health
CareFusion
Codan
Cook Medical
Covidien
Deltamed
Districlass Medical
Edwards Lifesciences
Endeavor Capital
Fresenius
Grupo Sendal
Interrad Medical
Investindustrial
Ivera Medical Corporation
Joline
Kimal
LPI
Medcomp
Medikit
Medtronic
Navilyst Medical
Nipro Medical
Nostix, LLC
Novico
Pentaferte
Perouse Medical
PFM Medical
PFM Medical
PositiveID Corp.
Rays
Romedex
Roundtable Healthcare
Safety Syringes Inc.
Semprus BioSciences
Smiths Medical
SonoSite, Inc.
Teleflex Medical
Terumo
Troge
Vascular Pathways, Inc.
VeriTeQ Acquisition Corp.
VigMed
V-Tech
Vygon